Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

SAN DIEGO--(BUSINESS WIRE)-- #PRVBstock--The suit alleges defendants issued false statements re: Provention Bio business and prospects, resulting in its stock trading at inflated prices.

Robbins Geller Rudman & Dowd LLP Announces Upcoming Lead Plaintiff Deadline in the Provention Bio, Inc. Class Action Lawsuit

New York, New York--(Newsfile Corp. - June 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...

PRVB Shareholder Update: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, June 2, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline. SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline - PRVB

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/p

PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

SAN DIEGO & RED BANK, N.J.--(BUSINESS WIRE)---- $PRVB #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, against the Company and certain of its officers for remedies under the Securities Exchange Act of 1934. Provention is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapeutics and solu

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders

Los Angeles, California--(Newsfile Corp. - June 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

RED BANK, N.J., June 1, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 AM E.T.

Provention Bio to Present at the Jefferies Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2021. SO WHAT: If you purchased Provention Bio securities during the Class Per

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB

An FDA advisory committee vote was a lot closer than anticipated.

Why Provention Bio Stock Crashed Today

LOS ANGELES--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). Provention investors have until July 20, 2021 to file a lead plaintiff motion. If you suffered a loss on your Pro

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of recommending approval of Provention Bio Inc's (NASDAQ: PRVB) teplizumab to delay the development of type 1 diabetes in high-risk children and adults, with most committee members expressing some concerns about trial size and safety. What Happened: In briefing documents released before the meeting, the FDA noted that the study, TN-10, was “relatively small,” with only 44 patients exposed to teplizumab; however, more than 750 patients with new-onset type 1 diabetes were exposed to teplizumab in other controlled clinical studies included in a meta-analysis.

FDA Advisory Committee Votes In Favor Of Approval Of Provention Bio's Diabetes Med

RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 10 yes and 7 no on the question, "Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?

FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)

NEW YORK, May 27, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - PRVB

LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors

SAN DIEGO & RED BANK, N.J.--(BUSINESS WIRE)---- $PRVB #ClassAction--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, against the Company and certain of its officers for remedies under the Securities Exchange Act of 1934. Provention is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapeutics and solutions to

SHAREHOLDER ALERT: Robbins LLP Announces that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders

BENSALEM, Pa.--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021, inclusive (the “Class Period”). Provention investors have until July 20, 2021 to file a lead plaintiff motion. Investors suffering losses on their Provention investments are encouraged to contact the Law Offices of Howard G

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors

Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Nasdaq has halted trading of the Company's common stock.

Provention Bio Stock Trading Halted Today

LOS ANGELES--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Provention investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors

The stock price of Provention Bio, Inc., (Nasdaq: PRVB) increased by 26.82% yesterday. This is why it happened.

PRVB Stock Price: 26.82% Increase Explanation

BENSALEM, Pa.--(BUSINESS WIRE)---- $PRVB #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) investors concerning the Company's possible violations of federal securities laws. In November 2020, Provention completed the rolling submission of a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for teplizumab for the delay or prevention of clinical T1D in at-risk individuals (the "tep

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Provention Bio, Inc. (PRVB) on Behalf of Investors

The FDA published Provention Bio Inc's (NASDAQ: PRVB) teplizumab-related briefing documents ahead of an Advisory Committee meeting scheduled for May 27 (Thursday). The agency sounded a relatively positive tone on safety and efficacy after identifying deficiencies that preclude discussion of labeling and post-marketing requirements.

Why Provention Bio Stock Is Trading Higher Today?

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB

The stock price of Provention Bio Inc (NASDAQ: PRVB) increased by over 20% during intraday trading this morning. This is why it happened.

News for Provention Bio Inc Stock (PRVB)